Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS (ALXN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Alexion Pharmaceuticals : Agrees to Work With Hedge Fund Elliott on Filling Board Seat--Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2018 | 01:08am CEST
By Aisha Al-Muslim 

Alexion Pharmaceuticals Inc. said Tuesday it will work with hedge fund Elliott Management Corp. on filling an open board seat.

The move comes as the rare-disease drugmaker has been facing pressure from the activist investor, which has pushed for changes in recent years at companies including aluminum parts maker Arconic Inc. and Brocade Communication Systems, now part of Broadcom Ltd.

The agreement between the board and Elliott is part of efforts to "maintain active and constructive dialogue with all of our shareholders, " Alexion Board Chairman David Brennan said in prepared remarks.

The New York Times reported last month, citing two unnamed sources, that Elliott had built a stake in Alexion and urged the company to make changes to lift its stock price.

Alexion said in November that it was searching for a candidate to fill a seat on its board, which currently has 11 members.

The company and Elliott declined to comment Tuesday on the size of Elliott's stake in the firm.

The New Haven, Conn., drugmaker, founded in 1992, has had many management changes during the past year, including hiring Chief Executive Ludwig Hantson in March, after an internal investigation showed senior management pressured staff to persuade customers to order its flagship drug earlier than needed to meet financial targets.

The company's primary product is a rare blood-disease treatment named Soliris.

Under Mr. Hantson's leadership, much of the senior management team was replaced. Alexion in September said it was cutting its workforce by 20%, relocating its headquarters to Boston and closing sites as it works to reduce its overhead. The moves were expected to create $250 million in annual cost savings by 2019.

"We are encouraged by actions taken under Ludwig's leadership to improve financial performance and reset Alexion's strategy," an Elliott spokesperson said in prepared remarks.

Shares in Alexion, down nearly 12% in the past three months, were unchanged at $124.05 in after-hours trading Tuesday. Alexion had a stock market value of $27.71 billion as of market close.

Write to Aisha Al-Muslim at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALEXION PHARMACEUTICALS
07/10ALEXION PHARMACEUTICALS : Abingworth closes BioVentures VII fund at $315M
AQ
07/03ALEXION PHARMACEUTICALS : Submits Application for Approval of ALXN1210 as a Trea..
AQ
07/03ALEXION PHARMACEUTICALS : to Report Second Quarter 2018 Results on Thursday, Jul..
AQ
06/29ALEXION PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-..
AQ
06/28ALEXION PHARMACEUTICALS : to Report Second Quarter 2018 Results on Thursday, Jul..
BU
06/28ALEXION PHARMACEUTICALS : Submits Application for Approval of ALXN1210 as a Trea..
BU
06/22ALEXION PHARMACEUTICALS : Submits Application For Priority Review And Approval O..
AQ
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19ALEXION PHARMACEUTICALS : Submits Application for Priority Review and Approval o..
BU
06/19SOLID BIOSCIENCES : FDA lifts clinical hold on Solid's DMD gene therapy
AQ
More news
News from SeekingAlpha
07/09Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt 
06/303 THINGS IN BIOTECH, JUNE 30 : Aptose Gets Rolling Again; Tesaro Heads To China;.. 
06/21YOUR DAILY PHARMA SCOOP : Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta S.. 
06/19Alexion files U.S. marketing application for ALXN1210 for PNH 
06/18A Review Of Adeno-Associated Virus Mediated Gene Therapies And A Closer Look .. 
Financials ($)
Sales 2018 4 000 M
EBIT 2018 1 954 M
Net income 2018 482 M
Debt 2018 1 400 M
Yield 2018 -
P/E ratio 2018 55,40
P/E ratio 2019 21,76
EV / Sales 2018 7,91x
EV / Sales 2019 5,80x
Capitalization 30 231 M
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 159 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP & Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS12.29%30 231
BIOGEN9.39%73 532
CSL LIMITED44.77%68 537
GRIFOLS4.73%18 363
BIOMARIN PHARMACEUTICAL16.19%18 309
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%12 638